Patents by Inventor Rodolfo Lavilla Grifols

Rodolfo Lavilla Grifols has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160168132
    Abstract: The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of ?-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 16, 2016
    Applicant: Minoryx Therapeutics S.L.
    Inventors: Xavier BARRIL ALONSO, Ana Maria GARCÍA COLLAZO, Juan AYMAMI BOFARULL, Marc REVÉS VILAPLANA, Rodolfo LAVILLA GRIFOLS, Marc MARTINELL PEDEMONTE
  • Patent number: 8680126
    Abstract: Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R1 is selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO—(C1-C6)-alkyl, and (C1-C6)-alkoxy; and R2 is a radical selected from the same group as R1, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH2)CONH(CH2)3CH3 and OCH2COOC(CH3)3, a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: March 25, 2014
    Assignees: Universitat de Barcelona, Fundacio Privada Institut d'Inbestigacio Biomedica de Bell Vitge, Fundacio Privada Institute de Recerca Biomedica de Barcelona, Fundacio Privada Parc Cientific de Barcelona
    Inventors: Joan Gil Santano, Rodolfo Lavilla Grifols, Fernando Albericio Palomera, Alba Pérez Perarnau, Sara Preciado Gallego, Diana Ma González Gironès, Daniel Iglesias Serret, Rosario Ramón Albalate
  • Publication number: 20130190367
    Abstract: Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R1 is selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO-(C1-C6)-alkyl, and (C1-C6)-alkoxy; and R2 is a radical selected from the same group as R1, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH2)CONH(CH2)3CH3 and OCH2COOC(CH3)3, a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer.
    Type: Application
    Filed: August 29, 2011
    Publication date: July 25, 2013
    Applicants: UNIVERSITAT DE BARCELONA, FUNDACIO PRIVADA INSTITUT DE RECERCA BIOMEDICA DE BARCELONA, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE, FUNDACIO PRIVADA PARC CIENTÍFIC DE BARCELONA
    Inventors: Joan Gil Santano, Rodolfo Lavilla Grífols, Fernando Albericio Palomera, Alba Pérez Perarnau, Sara Preciado Gallego, Diana Mª González Gironès, Daniel Iglesias Serret, Rosario Ramón Albalate